Scott M. McAhren
Eli Lilly and Company
5 Papers
1 Citations
Scott M. McAhren is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Type 2 diabetes & Sample collection. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Genome of the bacterium Streptococcus pneumoniae strain R6.
JoAnn Hoskins,William E. Alborn,Jeffrey S. Arnold,Larry C. Blaszczak,Stanley Gene Burgett,Bradley S. DeHoff,Shawn T. Estrem,Lori Fritz,Dong-Jing Fu,Wendy Fuller,Chad D. Geringer,Raymond Gilmour,Jennifer S. Glass,Hamid Khoja,Angelika R. Kraft,Robert E. Lagace,Donald J. LeBlanc,Linda N. Lee,Elliot J. Lefkowitz,Jin Lu,Patti Matsushima,Scott M. McAhren,Margaret A. Mchenney,Kevin McLeaster,Christopher W. Mundy,Thalia I. Nicas,Franklin H. Norris,MaryJeanne O'Gara,Robert B. Peery,Gregory T. Robertson,Pamela Kay Rockey,Pei-Ming Sun,Malcolm E. Winkler,Yong Yang,Michelle Young-Bellido,Genshi Zhao,Christopher A. Zook,Richard H. Baltz,S. Richard Jaskunas,Paul Robert Rosteck,Paul L. Skatrud,John I. Glass +41 more
TL;DR: In the analysis of the genome, a large number of new uncharacterized genes predicted to encode proteins that either reside on the surface of the cell or are secreted are identified and there may be new targets for vaccine and antibiotic development.
851
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data
Stefan Ravizza,Tony Huschto,Anja Adamov,Lars Böhm,Alexander Büsser,Frederik F. Flöther,Rolf Hinzmann,Helena König,Scott M. McAhren,Daniel H. Robertson,Titus Schleyer,Bernd Schneidinger,Wolfgang Petrich +12 more
TL;DR: An algorithm trained on half a million electronic medical records predicts chronic kidney disease in diabetic patients using a small set of defined clinical features, outperforming predictions derived from clinical trial data.
154
Rare DEGS1 variant significantly alters de novo ceramide synthesis pathway.
Nicholas B. Blackburn,Laura F. Michael,Peter J. Meikle,Juan M. Peralta,Marian Mosior,Scott M. McAhren,Hai H. Bui,Melissa A. Bellinger,Corey Giles,Satish Kumar,Ana C Leandro,Marcio Almeida,Jacquelyn M. Weir,Michael C. Mahaney,Thomas D. Dyer,Laura Almasy,John L. VandeBerg,Sarah Williams-Blangero,David C. Glahn,Ravindranath Duggirala,Mark C. Kowala,John Blangero,Joanne E. Curran +22 more
TL;DR: A Hispanic ancestry-specific rare functional variant is identified in delta 4-desaturase, sphingolipid 1 (DEGS1), a key enzyme in the pathway that converts dihydroceramide to ceramide, and it is confirmed that the L175Q variant results in a partial loss of function for the DEGS1 enzyme.
21
Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities
Michael Pugia,Meeta Pradhan,Rong Qi,Doreen L. Eastes,Anna Geisinger,Bradley J. Mills,Zane Baird,Aruna B. Wijeratne,Scott M. McAhren,Amber L. Mosley,Anantha Shekhar,Daniel H. Robertson +11 more
TL;DR: The immunoassay reference range for circulating autoantibodies against the C terminal fragment of adiponectin receptor 1 (IgG-CTF) was determined and used to predict outcomes post-sample and predicted increased likelihood of additional comorbidities and mortality determined from the EHRs 10 years after sample collection.
Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities.
Michael Pugia,Meeta Pradhan,Rong Qi,Doreen L. Eastes,Anna Vorsilak,Bradley J. Mills,Zane Baird,Aruna B. Wijeratne,Scott M. McAhren,Amber L. Mosley,Anantha Shekhar,Daniel H. Robertson +11 more
- 01 Jan 2020
TL;DR: In this paper, a 20-year observational study of type 2 diabetes and cardiovascular arterial disease (CVAD) conducted by the Fairbanks Institute was used to establish reference ranges for novel autoimmune diagnostic markers and provide insights into prediction of specific health outcomes and correlations to other markers.